Acute Respiratory Viral Infection
Conditions
Brief summary
The multicenter double-blind placebo-controlled randomized in parallel-group. The objective of this study is to evaluate efficacy and safety of Raphamin in the treatment of acute respiratory viral infection (ARVI) in children aged 12-18 years old.
Detailed description
Design: a multicenter, double-blind, placebo-controlled, parallel-group randomized clinical trial. The study will enroll outpatient subjects of either gender aged 12-18 old years with clinical manifestations of acute respiratory viral infection (ARVI) within the first days after the onset of the disease. The patients will be recruited during seasonal ARVI morbidity. Collection of history, thermometry, objective examination, laboratory tests, recording concomitant therapy will be made after parent/adoptive parent signing information sheet and informed consent form for the child participation in the clinical study, for children ≥14 years old after signing patient information sheet and informed consent form for children ≥14 years old to participate in the clinical study. The severity of ARVI symptoms will be evaluated with a 4-point scale. The nasopharyngeal swabs for PCR diagnosis and verification of respiratory viruses will be performed prior to therapy to confirm the viral etiology of ARVI. To rule out the infection caused by the new coronavirus COVID-19 (Coronavirus disease 2019), a rapid test for SARS-CoV-2 antigen will be made. In case of a positive SARS-CoV-2 test, the physician will act in accordance with the current version of the RF MoH Temporary methodological recommendations Prevention, diagnosis, and therapy of new coronavirus infection (COVID-19). If a patient meets all inclusion criteria and does not have any exclusion criteria, at Visit 1 (Day 1), he/she will be randomized into one of two groups: patients of group 1 will take Raphamin according to the dosage regimen for 5 days; patients of group 2 will take Placebo using Raphamin 5-day regimen. The study will use an electronic patient diary (EPD) for recording morning and evening axillary body temperature (using a classic mercury-free thermometer) and disease symptoms (Symptom Severity Score). Besides, antipyretic dosing (if applicable) and any deterioration in a patient's condition (if applicable, for safety evaluation/AE documentation) will also be recorded in a patient diary. The investigator will provide instructions on filling the diary. At Visit 1 the parent/adoptive parent together with an investigator will record ARVI symptom severity and body temperature in the diary. Patients will be observed for 14 days (screening, randomization - up to 1 day, treatment period - 5 days, follow-up - up to 2 days; deferred phone visit - day 14). During the treatment and follow-up period the patients/physicians will make 3 visits and the fourth phone visit will be scheduled additionally: 1) visits by physician/patient - on Days 1, 5, and 7 (Visits 1, 2, and 3) - in a study center or at home; 2) phone visit (Visit 4) - on Day 14. At Visits 2 and 3, the investigator will perform an objective examination, document changes in the symptoms and concomitant medications, and check patient diaries. At Visit 3 laboratory tests will be performed and compliance will be checked. Phone visit will be performed to interview parents/adoptive parents about the patient's condition, presence/absence of secondary bacterial/viral complications, and use of antibiotics. During the study, symptomatic therapy and therapy for their co-morbidities are allowed with the exception of the drugs indicated in the section Prohibited Concomitant Treatment.
Interventions
DRUGRaphamin
Oral administration - not with food. Keep the tablet in the mouth until it is completely dissolved. On the 1st day of treatment, 8 tablets are taken according to the following scheme: 1 tablet every 30 minutes in the first 2 hours (a total of 5 tablets in 2 hours), then during the same day, take another 1 tablet 3 times at regular intervals. On the 2nd day and then take 1 tablet 3 times a day. The duration of treatment is 5 days.
DRUGPlacebo
Oral administration - not with food. Placebo using Raphamin scheme.
Sponsors
Materia Medica Holding
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
12 Years to 18 Years
Healthy volunteers
No
Inclusion criteria
1. Patients of either gender aged 12 to 18 years. 2. Diagnosis of ARVI based on medical examination: axillary temperature ≥ 37.8°C at examination + non-specific flu-like symptoms score ≥4, nasal/throat/chest symptom score ≥2. 3. The first 24 hours after ARVI onset. 4. Contraceptive measures by sexually active adolescents of both genders during the study. 5. Patient information sheet (informed consent form) signed by one parent/adoptive parent of the patient and there is also a signed patient information sheet (informed consent form) for children aged 14 and over.
Exclusion criteria
1. Clinical symptoms of severe influenza/ARVI requiring hospitalization. 2. Positive SARS-CoV-2 (COVID-19/Coronavirusdisease2019) antigen test. 3. Suspected pneumonia, bacterial infection (including otitis media, sinusitis, urinary tract infection, meningitis, sepsis, etc.) requiring administration of antibiotics from the first day of illness. 4. Suspected initial manifestations of diseases with symptoms similar to ARVI at onset (other infectious diseases, flu-like syndrome at the onset of systemic connective tissue diseases, and other pathology). 5. Patients requiring antiviral medication prohibited within the study. 6. Medical history of primary and secondary immunodeficiency. 7. Medical history/suspicion of oncology of any localization (except for benign neoplasms). 8. Aggravation or decompensation of chronic diseases (diabetes mellitus, infantile cerebral paralysis, cystic fibrosis, primary ciliary dyskinesia, bronchopulmonary dysplasia, respiratory and ENT congenital defects, etc.) affecting a patient's ability to participate in the clinical trial. 9. Malabsorption syndrome, including congenital or acquired lactase or other disaccharidase deficiency, galactosemia. 10. Allergy/ hypersensitivity to any component of the study drugs used in the treatment. 11. Pregnancy. Breast-feeding. 12. Use of medications specified in the section Prohibited Concomitant Therapy within two weeks prior to inclusion in the study. 13. Patients whose parents/adopters, from the investigator's point of view, will not comply with the observation requirements during the study or follow the procedure for taking the study drugs. 14. Medical history of mental diseases of the patient or their parent(s)/adoptive parents. 15. Participation in other clinical trials for 3 months prior to enrollment in this study. 16. Patient's parents/adopters who are related to any of the on-site research personnel directly involved in the study or are an immediate relative of the investigator. 'Immediate relative' means husband, wife, parent, son, daughter, brother, or sister (regardless of whether they are natural or adopted). 17. The patient's parent/adopter who work for OOO NPF MATERIA MEDICA HOLDING (i.e. the company's employees, temporary contract workers, designated officials responsible for carrying out the research or any immediate relatives of the aforementioned).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Time to Resolution of Acute Respiratory Viral Infection (ARVI) Symptoms (ARVI, Confirmed by Polymerase Chain Reaction (PCR)). | 14 days of observation | Outcome Measure is evaluated on the basis of ARVI, confirmed by Polymerase chain reaction (PCR), i.e virus detection. ARVI's resolution criteria: temperature ≤37.3°С + total symptom score (TSS) ≤2. Axillar temperature, 6 flu-like nonspecific symptoms (headache, chills, sweating, weakness, muscle pain, drowsiness) and 7 nasal/throat/chest symptoms (runny nose, nasal congestion, sneezing, hoarseness, sore throat, cough, pain/heaviness in chest) were registered for TSS according to the 4-point scale for each of them (0 = no symptom; 1 = mild symptom; 2 = moderate symptom; 3 = severe symptom). To calculate TSS absolute axillar temperature (in degrees Celsius) was converted to relative units (or points) using the following scale: ≤37.3 С=0 points; 37.4-38.0 С=1 point; 38.1-39.0 С=2 points; ≥39.1 С=3 points. So the range of TSS was from 0 to 42. The TSS higher score is the worse outcome. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of Patients With Resolution of ARVI Symptoms (Clinically Diagnosed and/or PCR-confirmed). | 14 days of observation | ARVI's resolution criteria: temperature ≤37.3°С + total symptom score (TSS) ≤2. Axillar temperature, 6 flu-like nonspecific symptoms (headache, chills, sweating, weakness, muscle pain, drowsiness) and 7 nasal/throat/chest symptoms (runny nose, nasal congestion, sneezing, hoarseness, sore throat, cough, pain/heaviness in chest) were registered for TSS according to the 4-point scale for each of them (0 = no symptom; 1 = mild symptom; 2 = moderate symptom; 3 = severe symptom). To calculate TSS absolute axillar temperature (in degrees Celsius) was converted to relative units (or points) using the following scale: ≤37.3 С=0 points; 37.4-38.0 С=1 point; 38.1-39.0 С=2 points; ≥39.1 С=3 points. So the range of TSS was from 0 to 42. The TSS higher score is the worse outcome. |
| Time to Resolution of ARVI Symptoms (Clinically Diagnosed and/or PCR-confirmed). | 14 days of observation | ARVI's resolution criteria: temperature ≤37.3°С + total symptom score (TSS) ≤2. Axillar temperature, 6 flu-like nonspecific symptoms (headache, chills, sweating, weakness, muscle pain, drowsiness) and 7 nasal/throat/chest symptoms (runny nose, nasal congestion, sneezing, hoarseness, sore throat, cough, pain/heaviness in chest) were registered for TSS according to the 4-point scale for each of them (0 = no symptom; 1 = mild symptom; 2 = moderate symptom; 3 = severe symptom). To calculate TSS absolute axillar temperature (in degrees Celsius) was converted to relative units (or points) using the following scale: ≤37.3 С=0 points; 37.4-38.0 С=1 point; 38.1-39.0 С=2 points; ≥39.1 С=3 points. So the range of TSS was from 0 to 42. The TSS higher score is the worse outcome. |
| Percentage of Patients With Resolution of ARVI Symptoms (PCR-confirmed). | 14 days of observation | Outcome Measure is based on the Percentage of Patients With Resolution of ARVI, confirmed by Polymerase chain reaction (PCR), i.e virus detection. ARVI's resolution criteria: temperature ≤37.3°С + total symptom score (TSS) ≤2. Axillar temperature, 6 flu-like nonspecific symptoms (headache, chills, sweating, weakness, muscle pain, drowsiness) and 7 nasal/throat/chest symptoms (runny nose, nasal congestion, sneezing, hoarseness, sore throat, cough, pain/heaviness in chest) were registered for TSS according to the 4-point scale for each of them (0 = no symptom; 1 = mild symptom; 2 = moderate symptom; 3 = severe symptom). To calculate TSS absolute axillar temperature (in degrees Celsius) was converted to relative units (or points) using the following scale: ≤37.3 С=0 points; 37.4-38.0 С=1 point; 38.1-39.0 С=2 points; ≥39.1 С=3 points. So the range of TSS was from 0 to 42. The TSS higher score is the worse outcome. |
| Dosing Frequency of Antipyretics. | 3 days of therapy | Outcome Measure is based on the rates of antipyretic use per patient during days 1 to 3 of therapy according to the electronic patient diary. |
| Percentage of Patients Reporting Worsening of Illness. | Day 4 through day 14 of the treatment and observation period | Outcome Measure is based on the rates of Complications that require the use of antibiotics or hospitalization. |
| Severity of ARVI (Clinically Diagnosed and/or PCR-confirmed). | Day1 through Day6 of the treatment and observation | The outcome measure is based on the area under the curve (AUC) for the TSS (Total symptoms score). TSS is calculated as a sum of scores for 14 different symptoms. 13 of them are different ARVI manifestations, each of them is evaluated on a scale: 0 (none), 1 (mild), 2 (moderate), 3 (severe). 14th symptom is body temperature (temp) which is converted to its score using following rules: if temp \<= 37.3 then score = 0 (none) if 37.3 \< temp \<= 38.0 then score = 1 (mild) if 38.0 \< temp \<= 39.0 then score = 2 (moderate) if 39.0 \< temp then score = 3 (severe) So it is 14 symptoms and the score for each of them varies between 0 and 3. Minimum TSS is 0, maximum is 42 (higher TSS score is worse). AUC is calculated for all timepoints available for patient. |
| Changes in Vital Signs: Pulse Rate/Heart Rate in Beats Per Minute (Bpm). | Day 1 through day 7 of the treatment and observation period. | The outcome measure is based on the medical records. The patient's heart rate (heart rate) is measured by the physician in every visit (on days 1, 5, and 7). |
| Changes in Vital Signs: Respiration Rate/Breathing Rate in Breaths Per Minute. | Day 1 through day 7 of the treatment and observation period. | Outcome Measure is based on the medical records. The patient's respiration rate (breathing rate) is measured by physician in every visit (on days 1, 5, and 7). |
| Changes in Vital Signs: Blood Pressure in Units of Millimeters of Mercury (mmHg). | Day 1 through day 7 of the treatment and observation period. | Outcome Measure is based on the medical records. The patient's blood pressure is measured by the physician in every visit (on days 1, 5, and 7). |
| Percentage of Patients With Clinically Relevant Abnormal Laboratory Findings. | Day 1 through day 7 of the treatment and observation period. | Outcome Measure is based on the Hematology, blood chemistry, and urinalysis parameters, which are beyond the reference values at the end of treatment. |
| Occurrence and Type of Adverse Events (AE) During the Treatment. AE Severity. | 14 days of observation | 1. The intensity (severity) of adverse events. 2. Causal relationship of AEs to the sudy drug. 3. Outcome of AEs. Based on medical records. |
Countries
Russia
Participant flow
Pre-assignment details
A total of 435 patients signed informed consent, of which 10 patients did not pass screening (not meet inclusion criteria or non-inclusion criteria). 5 patients had significant deviations from the procedure for signing informed consent. However, they were randomized and received study therapy. But these patients are not counted as randomized.
Participants by arm
| Arm | Count |
|---|---|
| Raphamin Tablet for oral use.
Raphamin: Oral administration - not with food. Keep the tablet in the mouth until it is completely dissolved.
On the 1st day of treatment, 8 tablets are taken according to the following scheme: 1 tablet every 30 minutes in the first 2 hours (a total of 5 tablets in 2 hours), then during the same day, take another 1 tablet 3 times at regular intervals. On the 2nd day and then take 1 tablet 3 times a day. The duration of treatment is 5 days. | 199 |
| Placebo Tablet for oral use.
Placebo: Oral administration - not with food. Placebo using Raphamin scheme. | 205 |
| Total | 404 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Incorrect inclusion ineligible patient | 3 | 4 |
| Overall Study | Withdrawal by Subject | 4 | 5 |
Baseline characteristics
| Characteristic | Raphamin | Placebo | Total |
|---|---|---|---|
| Age, Continuous | 14.3 years STANDARD_DEVIATION 1.7 | 14.2 years STANDARD_DEVIATION 1.7 | 14.2 years STANDARD_DEVIATION 1.7 |
| Age, Customized 12 to 18 years | 199 Participants | 205 Participants | 404 Participants |
| Race and Ethnicity Not Collected | — | — | 0 Participants |
| Region of Enrollment Russia | 199 participants | 205 participants | 404 participants |
| Sex: Female, Male Female | 100 Participants | 107 Participants | 207 Participants |
| Sex: Female, Male Male | 99 Participants | 98 Participants | 197 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 206 | 0 / 214 |
| other Total, other adverse events | 6 / 206 | 5 / 214 |
| serious Total, serious adverse events | 1 / 206 | 0 / 214 |
Outcome results
Primary
Time to Resolution of Acute Respiratory Viral Infection (ARVI) Symptoms (ARVI, Confirmed by Polymerase Chain Reaction (PCR)).
Outcome Measure is evaluated on the basis of ARVI, confirmed by Polymerase chain reaction (PCR), i.e virus detection. ARVI's resolution criteria: temperature ≤37.3°С + total symptom score (TSS) ≤2. Axillar temperature, 6 flu-like nonspecific symptoms (headache, chills, sweating, weakness, muscle pain, drowsiness) and 7 nasal/throat/chest symptoms (runny nose, nasal congestion, sneezing, hoarseness, sore throat, cough, pain/heaviness in chest) were registered for TSS according to the 4-point scale for each of them (0 = no symptom; 1 = mild symptom; 2 = moderate symptom; 3 = severe symptom). To calculate TSS absolute axillar temperature (in degrees Celsius) was converted to relative units (or points) using the following scale: ≤37.3 С=0 points; 37.4-38.0 С=1 point; 38.1-39.0 С=2 points; ≥39.1 С=3 points. So the range of TSS was from 0 to 42. The TSS higher score is the worse outcome.
Time frame: 14 days of observation
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Raphamin | Time to Resolution of Acute Respiratory Viral Infection (ARVI) Symptoms (ARVI, Confirmed by Polymerase Chain Reaction (PCR)). | 3.3 day | Standard Deviation 1.7 |
| Placebo | Time to Resolution of Acute Respiratory Viral Infection (ARVI) Symptoms (ARVI, Confirmed by Polymerase Chain Reaction (PCR)). | 4.4 day | Standard Deviation 2.6 |
Comparison: Mean time to resolution of ARVI symptomsp-value: 0.000395% CI: [0.51, 1.67]t-test, 2 sided
Secondary
Changes in Vital Signs: Blood Pressure in Units of Millimeters of Mercury (mmHg).
Outcome Measure is based on the medical records. The patient's blood pressure is measured by the physician in every visit (on days 1, 5, and 7).
Time frame: Day 1 through day 7 of the treatment and observation period.
Population: Only non-missing values were analyzed, so numbers analyzed are a bit lower then overall number of participants for visits 2 and 3.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Raphamin | Changes in Vital Signs: Blood Pressure in Units of Millimeters of Mercury (mmHg). | Visit 1/Systolic blood pressure | 112 mmHg | Standard Deviation 9.9 |
| Raphamin | Changes in Vital Signs: Blood Pressure in Units of Millimeters of Mercury (mmHg). | Visit 2/Systolic blood pressure | 111 mmHg | Standard Deviation 9.8 |
| Raphamin | Changes in Vital Signs: Blood Pressure in Units of Millimeters of Mercury (mmHg). | Visit 3/Systolic blood pressure | 111 mmHg | Standard Deviation 10.2 |
| Raphamin | Changes in Vital Signs: Blood Pressure in Units of Millimeters of Mercury (mmHg). | Visit 1/Diastolic blood pressure | 70.0 mmHg | Standard Deviation 5.7 |
| Raphamin | Changes in Vital Signs: Blood Pressure in Units of Millimeters of Mercury (mmHg). | Visit 2/Diastolic blood pressure | 69.7 mmHg | Standard Deviation 5.7 |
| Raphamin | Changes in Vital Signs: Blood Pressure in Units of Millimeters of Mercury (mmHg). | Visit 3/Diastolic blood pressure | 69.6 mmHg | Standard Deviation 5.7 |
| Placebo | Changes in Vital Signs: Blood Pressure in Units of Millimeters of Mercury (mmHg). | Visit 2/Diastolic blood pressure | 69.5 mmHg | Standard Deviation 5.4 |
| Placebo | Changes in Vital Signs: Blood Pressure in Units of Millimeters of Mercury (mmHg). | Visit 1/Systolic blood pressure | 112 mmHg | Standard Deviation 8.9 |
| Placebo | Changes in Vital Signs: Blood Pressure in Units of Millimeters of Mercury (mmHg). | Visit 1/Diastolic blood pressure | 69.8 mmHg | Standard Deviation 5.8 |
| Placebo | Changes in Vital Signs: Blood Pressure in Units of Millimeters of Mercury (mmHg). | Visit 2/Systolic blood pressure | 112 mmHg | Standard Deviation 8.7 |
| Placebo | Changes in Vital Signs: Blood Pressure in Units of Millimeters of Mercury (mmHg). | Visit 3/Diastolic blood pressure | 69.4 mmHg | Standard Deviation 5.9 |
| Placebo | Changes in Vital Signs: Blood Pressure in Units of Millimeters of Mercury (mmHg). | Visit 3/Systolic blood pressure | 111 mmHg | Standard Deviation 9.4 |
Comparison: Comparison for Visit 1/Systolic blood pressure.p-value: 0.661Median test
Comparison: Comparison for Visit 2/Systolic blood pressure.p-value: 0.4884Median test
Comparison: Comparison for Visit 3/Systolic blood pressure.p-value: 0.3494Median test
Comparison: Comparison for Visit 1/Diastolic blood pressure.p-value: 0.9531Median test
Comparison: Comparison for Visit 2/Diastolic blood pressure.p-value: 0.5506Median test
Comparison: Comparison for Visit 3/Diastolic blood pressure.p-value: 0.8259Median test
Secondary
Changes in Vital Signs: Pulse Rate/Heart Rate in Beats Per Minute (Bpm).
The outcome measure is based on the medical records. The patient's heart rate (heart rate) is measured by the physician in every visit (on days 1, 5, and 7).
Time frame: Day 1 through day 7 of the treatment and observation period.
Population: Only non-missing values were analyzed, so numbers analyzed are a bit lower then overall number of participants for visits 2 and 3.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Raphamin | Changes in Vital Signs: Pulse Rate/Heart Rate in Beats Per Minute (Bpm). | Visit 1 | 87.1 beats per minute | Standard Deviation 11.4 |
| Raphamin | Changes in Vital Signs: Pulse Rate/Heart Rate in Beats Per Minute (Bpm). | Visit 2 | 77.9 beats per minute | Standard Deviation 7.1 |
| Raphamin | Changes in Vital Signs: Pulse Rate/Heart Rate in Beats Per Minute (Bpm). | Visit 3 | 76.3 beats per minute | Standard Deviation 7 |
| Placebo | Changes in Vital Signs: Pulse Rate/Heart Rate in Beats Per Minute (Bpm). | Visit 1 | 87.2 beats per minute | Standard Deviation 10.6 |
| Placebo | Changes in Vital Signs: Pulse Rate/Heart Rate in Beats Per Minute (Bpm). | Visit 2 | 78.1 beats per minute | Standard Deviation 7.2 |
| Placebo | Changes in Vital Signs: Pulse Rate/Heart Rate in Beats Per Minute (Bpm). | Visit 3 | 76.7 beats per minute | Standard Deviation 6.8 |
Comparison: Comparison for Visit 1.p-value: 0.7848Median test
Comparison: Comparison for Visit 2.p-value: 0.9596Median test
Comparison: Comparison for Visit 3.p-value: 0.6902Median test
Secondary
Changes in Vital Signs: Respiration Rate/Breathing Rate in Breaths Per Minute.
Outcome Measure is based on the medical records. The patient's respiration rate (breathing rate) is measured by physician in every visit (on days 1, 5, and 7).
Time frame: Day 1 through day 7 of the treatment and observation period.
Population: Only non-missing values were analyzed, so numbers analyzed are a bit lower then overall number of participants for visits 2 and 3.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Raphamin | Changes in Vital Signs: Respiration Rate/Breathing Rate in Breaths Per Minute. | Visit 1 | 20.8 breaths per minute | Standard Deviation 3.3 |
| Raphamin | Changes in Vital Signs: Respiration Rate/Breathing Rate in Breaths Per Minute. | Visit 2 | 18.4 breaths per minute | Standard Deviation 1.9 |
| Raphamin | Changes in Vital Signs: Respiration Rate/Breathing Rate in Breaths Per Minute. | Visit 3 | 18.0 breaths per minute | Standard Deviation 1.7 |
| Placebo | Changes in Vital Signs: Respiration Rate/Breathing Rate in Breaths Per Minute. | Visit 1 | 20.7 breaths per minute | Standard Deviation 2.8 |
| Placebo | Changes in Vital Signs: Respiration Rate/Breathing Rate in Breaths Per Minute. | Visit 2 | 18.6 breaths per minute | Standard Deviation 1.7 |
| Placebo | Changes in Vital Signs: Respiration Rate/Breathing Rate in Breaths Per Minute. | Visit 3 | 18.2 breaths per minute | Standard Deviation 1.7 |
Comparison: Comparison for Visit 1.p-value: 0.3266Median test
Comparison: Comparison for Visit 2.p-value: 0.093Median test
Comparison: Comparison for Visit 3.p-value: 0.2308Median test
Secondary
Dosing Frequency of Antipyretics.
Outcome Measure is based on the rates of antipyretic use per patient during days 1 to 3 of therapy according to the electronic patient diary.
Time frame: 3 days of therapy
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Raphamin | Dosing Frequency of Antipyretics. | Day 1 | 0.43 number of doses | Standard Deviation 0.72 |
| Raphamin | Dosing Frequency of Antipyretics. | Day 2 | 0.22 number of doses | Standard Deviation 0.61 |
| Raphamin | Dosing Frequency of Antipyretics. | Day 3 | 0.09 number of doses | Standard Deviation 0.38 |
| Placebo | Dosing Frequency of Antipyretics. | Day 2 | 0.25 number of doses | Standard Deviation 0.66 |
| Placebo | Dosing Frequency of Antipyretics. | Day 1 | 0.39 number of doses | Standard Deviation 0.72 |
| Placebo | Dosing Frequency of Antipyretics. | Day 3 | 0.07 number of doses | Standard Deviation 0.31 |
Comparison: Dosing Frequency of Antipyretics. Comparison for Day 1.p-value: 0.3627Wilcoxon (Mann-Whitney)
Comparison: Dosing Frequency of Antipyretics. Comparison for Day 2.p-value: 0.5578Wilcoxon (Mann-Whitney)
Comparison: Dosing Frequency of Antipyretics. Comparison for Day 3.p-value: 0.7688Wilcoxon (Mann-Whitney)
Secondary
Occurrence and Type of Adverse Events (AE) During the Treatment. AE Severity.
1. The intensity (severity) of adverse events. 2. Causal relationship of AEs to the sudy drug. 3. Outcome of AEs. Based on medical records.
Time frame: 14 days of observation
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Raphamin | Occurrence and Type of Adverse Events (AE) During the Treatment. AE Severity. | Causal relationship/Not connected | 7 number of cases |
| Raphamin | Occurrence and Type of Adverse Events (AE) During the Treatment. AE Severity. | Outcome/Recovery | 6 number of cases |
| Raphamin | Occurrence and Type of Adverse Events (AE) During the Treatment. AE Severity. | Severity/Moderate | 5 number of cases |
| Raphamin | Occurrence and Type of Adverse Events (AE) During the Treatment. AE Severity. | Outcome/Unknown | 1 number of cases |
| Raphamin | Occurrence and Type of Adverse Events (AE) During the Treatment. AE Severity. | Severity/Mild | 2 number of cases |
| Placebo | Occurrence and Type of Adverse Events (AE) During the Treatment. AE Severity. | Outcome/Unknown | 1 number of cases |
| Placebo | Occurrence and Type of Adverse Events (AE) During the Treatment. AE Severity. | Severity/Mild | 6 number of cases |
| Placebo | Occurrence and Type of Adverse Events (AE) During the Treatment. AE Severity. | Severity/Moderate | 0 number of cases |
| Placebo | Occurrence and Type of Adverse Events (AE) During the Treatment. AE Severity. | Outcome/Recovery | 5 number of cases |
| Placebo | Occurrence and Type of Adverse Events (AE) During the Treatment. AE Severity. | Causal relationship/Not connected | 6 number of cases |
Comparison: Comparison of severity distributions.p-value: 0.021Fisher Exact
Comparison: Comparison for outcome distribution.p-value: 1Fisher Exact
Secondary
Percentage of Patients Reporting Worsening of Illness.
Outcome Measure is based on the rates of Complications that require the use of antibiotics or hospitalization.
Time frame: Day 4 through day 14 of the treatment and observation period
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Raphamin | Percentage of Patients Reporting Worsening of Illness. | 1 Participants |
| Placebo | Percentage of Patients Reporting Worsening of Illness. | 0 Participants |
p-value: 0.4926Fisher Exact
Secondary
Percentage of Patients With Clinically Relevant Abnormal Laboratory Findings.
Outcome Measure is based on the Hematology, blood chemistry, and urinalysis parameters, which are beyond the reference values at the end of treatment.
Time frame: Day 1 through day 7 of the treatment and observation period.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Raphamin | Percentage of Patients With Clinically Relevant Abnormal Laboratory Findings. | 1 Participants |
| Placebo | Percentage of Patients With Clinically Relevant Abnormal Laboratory Findings. | 0 Participants |
p-value: 0.49Fisher Exact
Secondary
Percentage of Patients With Resolution of ARVI Symptoms (Clinically Diagnosed and/or PCR-confirmed).
ARVI's resolution criteria: temperature ≤37.3°С + total symptom score (TSS) ≤2. Axillar temperature, 6 flu-like nonspecific symptoms (headache, chills, sweating, weakness, muscle pain, drowsiness) and 7 nasal/throat/chest symptoms (runny nose, nasal congestion, sneezing, hoarseness, sore throat, cough, pain/heaviness in chest) were registered for TSS according to the 4-point scale for each of them (0 = no symptom; 1 = mild symptom; 2 = moderate symptom; 3 = severe symptom). To calculate TSS absolute axillar temperature (in degrees Celsius) was converted to relative units (or points) using the following scale: ≤37.3 С=0 points; 37.4-38.0 С=1 point; 38.1-39.0 С=2 points; ≥39.1 С=3 points. So the range of TSS was from 0 to 42. The TSS higher score is the worse outcome.
Time frame: 14 days of observation
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Raphamin | Percentage of Patients With Resolution of ARVI Symptoms (Clinically Diagnosed and/or PCR-confirmed). | Day 2 | 24 Participants |
| Raphamin | Percentage of Patients With Resolution of ARVI Symptoms (Clinically Diagnosed and/or PCR-confirmed). | Day 3 | 64 Participants |
| Raphamin | Percentage of Patients With Resolution of ARVI Symptoms (Clinically Diagnosed and/or PCR-confirmed). | Day 5 | 149 Participants |
| Raphamin | Percentage of Patients With Resolution of ARVI Symptoms (Clinically Diagnosed and/or PCR-confirmed). | Day 7 | 191 Participants |
| Raphamin | Percentage of Patients With Resolution of ARVI Symptoms (Clinically Diagnosed and/or PCR-confirmed). | Day 6 | 174 Participants |
| Raphamin | Percentage of Patients With Resolution of ARVI Symptoms (Clinically Diagnosed and/or PCR-confirmed). | Day 4 | 96 Participants |
| Placebo | Percentage of Patients With Resolution of ARVI Symptoms (Clinically Diagnosed and/or PCR-confirmed). | Day 4 | 94 Participants |
| Placebo | Percentage of Patients With Resolution of ARVI Symptoms (Clinically Diagnosed and/or PCR-confirmed). | Day 6 | 162 Participants |
| Placebo | Percentage of Patients With Resolution of ARVI Symptoms (Clinically Diagnosed and/or PCR-confirmed). | Day 3 | 46 Participants |
| Placebo | Percentage of Patients With Resolution of ARVI Symptoms (Clinically Diagnosed and/or PCR-confirmed). | Day 2 | 16 Participants |
| Placebo | Percentage of Patients With Resolution of ARVI Symptoms (Clinically Diagnosed and/or PCR-confirmed). | Day 7 | 181 Participants |
| Placebo | Percentage of Patients With Resolution of ARVI Symptoms (Clinically Diagnosed and/or PCR-confirmed). | Day 5 | 136 Participants |
p-value: <0.0001Cochran-Mantel-Haenszel
Secondary
Percentage of Patients With Resolution of ARVI Symptoms (PCR-confirmed).
Outcome Measure is based on the Percentage of Patients With Resolution of ARVI, confirmed by Polymerase chain reaction (PCR), i.e virus detection. ARVI's resolution criteria: temperature ≤37.3°С + total symptom score (TSS) ≤2. Axillar temperature, 6 flu-like nonspecific symptoms (headache, chills, sweating, weakness, muscle pain, drowsiness) and 7 nasal/throat/chest symptoms (runny nose, nasal congestion, sneezing, hoarseness, sore throat, cough, pain/heaviness in chest) were registered for TSS according to the 4-point scale for each of them (0 = no symptom; 1 = mild symptom; 2 = moderate symptom; 3 = severe symptom). To calculate TSS absolute axillar temperature (in degrees Celsius) was converted to relative units (or points) using the following scale: ≤37.3 С=0 points; 37.4-38.0 С=1 point; 38.1-39.0 С=2 points; ≥39.1 С=3 points. So the range of TSS was from 0 to 42. The TSS higher score is the worse outcome.
Time frame: 14 days of observation
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Raphamin | Percentage of Patients With Resolution of ARVI Symptoms (PCR-confirmed). | Day 2 | 16 Participants |
| Raphamin | Percentage of Patients With Resolution of ARVI Symptoms (PCR-confirmed). | Day 3 | 36 Participants |
| Raphamin | Percentage of Patients With Resolution of ARVI Symptoms (PCR-confirmed). | Day 4 | 59 Participants |
| Raphamin | Percentage of Patients With Resolution of ARVI Symptoms (PCR-confirmed). | Day 5 | 95 Participants |
| Raphamin | Percentage of Patients With Resolution of ARVI Symptoms (PCR-confirmed). | Day 7 | 119 Participants |
| Raphamin | Percentage of Patients With Resolution of ARVI Symptoms (PCR-confirmed). | Day 6 | 107 Participants |
| Placebo | Percentage of Patients With Resolution of ARVI Symptoms (PCR-confirmed). | Day 6 | 77 Participants |
| Placebo | Percentage of Patients With Resolution of ARVI Symptoms (PCR-confirmed). | Day 2 | 4 Participants |
| Placebo | Percentage of Patients With Resolution of ARVI Symptoms (PCR-confirmed). | Day 3 | 16 Participants |
| Placebo | Percentage of Patients With Resolution of ARVI Symptoms (PCR-confirmed). | Day 4 | 39 Participants |
| Placebo | Percentage of Patients With Resolution of ARVI Symptoms (PCR-confirmed). | Day 7 | 89 Participants |
| Placebo | Percentage of Patients With Resolution of ARVI Symptoms (PCR-confirmed). | Day 5 | 64 Participants |
p-value: <0.0001Cochran-Mantel-Haenszel
Secondary
Severity of ARVI (Clinically Diagnosed and/or PCR-confirmed).
The outcome measure is based on the area under the curve (AUC) for the TSS (Total symptoms score). TSS is calculated as a sum of scores for 14 different symptoms. 13 of them are different ARVI manifestations, each of them is evaluated on a scale: 0 (none), 1 (mild), 2 (moderate), 3 (severe). 14th symptom is body temperature (temp) which is converted to its score using following rules: if temp \<= 37.3 then score = 0 (none) if 37.3 \< temp \<= 38.0 then score = 1 (mild) if 38.0 \< temp \<= 39.0 then score = 2 (moderate) if 39.0 \< temp then score = 3 (severe) So it is 14 symptoms and the score for each of them varies between 0 and 3. Minimum TSS is 0, maximum is 42 (higher TSS score is worse). AUC is calculated for all timepoints available for patient.
Time frame: Day1 through Day6 of the treatment and observation
Population: Two subpopulations were analysed:~1. Patients with clinically diagnosed and/or PCR-confirmed ARVI.~2. Patients with PCR-confirmed ARVI strictly.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Raphamin | Severity of ARVI (Clinically Diagnosed and/or PCR-confirmed). | Severity of ARVI (Clinically Diagnosed and/or PCR-confirmed), AUC score | 44.6 scores on a scale*days | Standard Deviation 23.8 |
| Raphamin | Severity of ARVI (Clinically Diagnosed and/or PCR-confirmed). | Severity of ARVI (PCR-confirmed), AUC score | 48.3 scores on a scale*days | Standard Deviation 25.2 |
| Placebo | Severity of ARVI (Clinically Diagnosed and/or PCR-confirmed). | Severity of ARVI (Clinically Diagnosed and/or PCR-confirmed), AUC score | 46.9 scores on a scale*days | Standard Deviation 24.3 |
| Placebo | Severity of ARVI (Clinically Diagnosed and/or PCR-confirmed). | Severity of ARVI (PCR-confirmed), AUC score | 53.6 scores on a scale*days | Standard Deviation 25.6 |
Comparison: Mean AUC score for severity of ARVI (Clinically Diagnosed and/or PCR-confirmed).p-value: 0.327495% CI: [-2.36, 7.06]t-test, 2 sided
Comparison: Mean AUC score for severity of ARVI (PCR-confirmed).p-value: 0.117195% CI: [-1.34, 11.93]t-test, 2 sided
Secondary
Time to Resolution of ARVI Symptoms (Clinically Diagnosed and/or PCR-confirmed).
ARVI's resolution criteria: temperature ≤37.3°С + total symptom score (TSS) ≤2. Axillar temperature, 6 flu-like nonspecific symptoms (headache, chills, sweating, weakness, muscle pain, drowsiness) and 7 nasal/throat/chest symptoms (runny nose, nasal congestion, sneezing, hoarseness, sore throat, cough, pain/heaviness in chest) were registered for TSS according to the 4-point scale for each of them (0 = no symptom; 1 = mild symptom; 2 = moderate symptom; 3 = severe symptom). To calculate TSS absolute axillar temperature (in degrees Celsius) was converted to relative units (or points) using the following scale: ≤37.3 С=0 points; 37.4-38.0 С=1 point; 38.1-39.0 С=2 points; ≥39.1 С=3 points. So the range of TSS was from 0 to 42. The TSS higher score is the worse outcome.
Time frame: 14 days of observation
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Raphamin | Time to Resolution of ARVI Symptoms (Clinically Diagnosed and/or PCR-confirmed). | 3.4 day | Standard Deviation 1.8 |
| Placebo | Time to Resolution of ARVI Symptoms (Clinically Diagnosed and/or PCR-confirmed). | 3.9 day | Standard Deviation 2.4 |
Comparison: The mean time to Resolution of ARVI Symptoms was analysed.p-value: 0.007395% CI: [0.16, 1]t-test, 2 sided